- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Angiopoietin-2.
Displaying page 1 of 1.
EudraCT Number: 2020-001172-15 | Sponsor Protocol Number: APN01-01-COVID19 | Start Date*: 2020-04-08 |
Sponsor Name:APEIRON Biologics AG | ||
Full Title: Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19 | ||
Medical condition: Severe COVID-19 POSITIVE hospitalized male or female, between 18 and ≤ 80 years of age | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2019-003765-18 | Sponsor Protocol Number: AIFA-TRS-2018-00001238 | Start Date*: 2020-03-20 | |||||||||||
Sponsor Name:DIPARTIMENTO AD ATTIVITÃ INTEGRATA CHIRURGICO, MEDICO, ODONTOIATRICO E DI SCIENZE MORFOLOGICHE | |||||||||||||
Full Title: Gender-related response to Tyrosine Kinase-Inhibitor drugs in hepatocellular carcinoma | |||||||||||||
Medical condition: Patients with advanced hepatocellular carcinoma only eligible for systemic treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002994-39 | Sponsor Protocol Number: Cx611-0204 | Start Date*: 2016-04-06 |
Sponsor Name:TIGENIX, S.A.U. | ||
Full Title: A phase Ib/IIa, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for... | ||
Medical condition: Severe community-acquired bacterial pneumonia requiring mechanical ventilation and/or vasopressors. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) BE (Completed) LT (Completed) GB (Completed) FR (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-002190-33 | Sponsor Protocol Number: B1131004 | Start Date*: 2012-02-02 | |||||||||||
Sponsor Name:PFIZER, S.L.U. | |||||||||||||
Full Title: A PHASE II TRIAL OF PF-04856884 (CVX-060), A SELECTIVE ANGIOPOIETIN 2 (ANG-2) INHIBITOR IN COMBINATION WITH AG-013736 (AXITINIB) IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC RENAL CELL CARCINOMA | |||||||||||||
Medical condition: METASTATIC RENAL CELL CARCINOMA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Completed) CZ (Completed) DE (Prematurely Ended) GB (Completed) AT (Completed) FI (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
